{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T02:07:25Z","timestamp":1790647645155,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,3,7]],"date-time":"2018-03-07T00:00:00Z","timestamp":1520380800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010643","name":"Cidara Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010643","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.jgar.2018.02.013","type":"journal-article","created":{"date-parts":[[2018,2,24]],"date-time":"2018-02-24T02:37:34Z","timestamp":1519439854000},"page":"58-64","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":93,"special_numbering":"C","title":["Rezafungin (CD101), a next-generation echinocandin: A systematic literature review and assessment of possible place in therapy"],"prefix":"10.1016","volume":"14","author":[{"given":"Amelia K.","family":"Sofjan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ardath","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhara N.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mui","family":"Sim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Trojcak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas D.","family":"Beyda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2063-7503","authenticated-orcid":false,"given":"Kevin W.","family":"Garey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2018.02.013_bib0005","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1086\/504810","article-title":"Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study","volume":"43","author":"Garey","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2018.02.013_bib0010","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2018.02.013_bib0015","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1056\/NEJMoa066906","article-title":"Anidulafungin versus fluconazole for invasive candidiasis","volume":"356","author":"Reboli","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgar.2018.02.013_bib0020","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/MAJ.0000000000000412","article-title":"Echinocandin use in hospitalized patients: a multi-institutional study","volume":"349","author":"Garey","year":"2015","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.jgar.2018.02.013_bib0025","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1093\/jac\/dkr244","article-title":"Evaluation of antifungal therapy in patients with candidaemia based on susceptibility testing results: implications for antimicrobial stewardship programmes","volume":"66","author":"Shah","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2018.02.013_bib0030","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1093\/cid\/ciu407","article-title":"FKS mutant Candida glabrata: risk factors and outcomes in patients with candidemia","volume":"59","author":"Beyda","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2018.02.013_bib0035","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1345\/aph.1R020","article-title":"Echinocandin resistance in Candida species: mechanisms of reduced susceptibility and therapeutic approaches","volume":"46","author":"Beyda","year":"2012","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jgar.2018.02.013_bib0040","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/pds.1365","article-title":"Inadequacy of fluconazole dosing in patients with candidemia based on Infectious Diseases Society of America (IDSA) guidelines","volume":"16","author":"Garey","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jgar.2018.02.013_bib0045","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.3109\/10428194.2014.885514","article-title":"Safety of high-dose micafungin for patients with hematological diseases","volume":"55","author":"Yamazaki","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jgar.2018.02.013_bib0050","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1007\/s00277-011-1277-1","article-title":"Efficacy and safety of micafungin as an empirical therapy for invasive fungal infections in patients with hematologic disorders: a multicenter, prospective study","volume":"90","author":"Yamaguchi","year":"2011","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jgar.2018.02.013_bib0055","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jgar.2018.02.013_bib0060","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1128\/CMR.18.4.638-656.2005","article-title":"Antimicrobial stewardship programs in health care systems","volume":"18","author":"MacDougall","year":"2005","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jgar.2018.02.013_bib0065","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/ja.2016.89","article-title":"CD101, a novel echinocandin with exceptional stability properties and enhanced aqueous solubility","volume":"70","author":"Krishnan","year":"2017","journal-title":"J Antibiot (Tokyo)"},{"key":"10.1016\/j.jgar.2018.02.013_bib0070","doi-asserted-by":"crossref","first-page":"6872","DOI":"10.1128\/AAC.00701-16","article-title":"Preclinical evaluation of the stability, safety, and efficacy of CD101, a novel echinocandin","volume":"60","author":"Ong","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2018.02.013_bib0075","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02045-16","article-title":"Activity of a long-acting echinocandin (CD101) and seven comparator antifungal agents tested against a global collection of contemporary invasive fungal isolates in the SENTRY (2014) Antifungal Surveillance Program","volume":"61","author":"Pfaller","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2018.02.013_bib0080","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1093\/jac\/dkw214","article-title":"Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, against Candida and Aspergillus spp., including echinocandin- and azole-resistant isolates","volume":"71","author":"Pfaller","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2018.02.013_bib0085","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/cmi.12640","article-title":"CD101: a novel long-acting echinocandin","volume":"18","author":"Zhao","year":"2016","journal-title":"Cell Microbiol"},{"key":"10.1016\/j.jgar.2018.02.013_bib0090","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ijantimicag.2017.03.028","article-title":"CD101, a long-acting echinocandin, and comparator antifungal agents tested against a global collection of invasive fungal isolates in the SENTRY 2015 Antifungal Surveillance Program","volume":"50","author":"Pfaller","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2018.02.013_bib0095","article-title":"Structure\u2013activity relationships of a series of echinocandins and the discovery of CD101, a highly stable and soluble echinocandin with distinctive pharmacokinetic properties","volume":"61","author":"James","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2018.02.013_bib0100","series-title":"55th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)\/International Congress of Chemotherapy and Infection (ICC)","article-title":"Evaluation of disk diffusion susceptibility testing for CD101, a novel echinocandin, against Candida spp","author":"Stoneburner","year":"2015"},{"key":"10.1016\/j.jgar.2018.02.013_bib0105","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1093\/jac\/dkx008","article-title":"In vitro activity of the novel echinocandin CD101 at pH 7 and 4 against Candida spp. isolates from patients with vulvovaginal candidiasis","volume":"72","author":"Boikov","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2018.02.013_bib0110","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01750-17","article-title":"CD101, a novel echinocandin, possesses potent antibiofilm activity against early and mature Candida albicans biofilms","volume":"62","author":"Chandra","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2018.02.013_bib0115","doi-asserted-by":"crossref","first-page":"6100","DOI":"10.1128\/AAC.00620-16","article-title":"Characterization of in vitro resistance development to the novel echinocandin CD101 in Candida species","volume":"60","author":"Locke","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2018.02.013_bib0120","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01626-16","article-title":"Pharmacokinetics of the novel echinocandin, CD101, in multiple animal species","volume":"61","author":"Ong","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2018.02.013_bib0125","series-title":"ASM Microbe","article-title":"Tissue distribution\/penetration and pharmacokinetics of CD101","author":"Zhao","year":"2016"},{"key":"10.1016\/j.jgar.2018.02.013_bib0130","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01009-17","article-title":"Unraveling drug penetration of echinocandin antifungals at the site of infection in an intra-abdominal abscess model","volume":"61","author":"Zhao","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2018.02.013_bib0135","series-title":"55th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)","article-title":"Pharmacokinetics pharmacodynamics (PKPD) of a novel echinocandin, CD101, in a neutropenic murine disseminated candidiasis model","author":"Rubino","year":"2015"},{"key":"10.1016\/j.jgar.2018.02.013_bib0140","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02154-17","article-title":"Pharmacodynamics of a long-acting echinocandin, CD101, in a neutropenic invasive-candidiasis murine model using an extended-interval dosing design","volume":"62","author":"Lepak","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2018.02.013_bib0145","series-title":"ASM Microbe","article-title":"Pharmacological basis of CD101 efficacy: exposure shape matters","author":"Lakota","year":"2016"},{"key":"10.1016\/j.jgar.2018.02.013_bib0150","series-title":"ASM Microbe","article-title":"Efficacy of a novel echinocandin, CD101, in a mouse model of azole-resistant disseminated candidiasis","author":"Miesel","year":"2016"},{"key":"10.1016\/j.jgar.2018.02.013_bib0155","series-title":"7th Advances Against Aspergillosis Conference","article-title":"Efficacy of CD101, a novel echinocandin antifungal, in a mouse model of disseminated aspergillosis","author":"Ong","year":"2016"},{"key":"10.1016\/j.jgar.2018.02.013_bib0160","series-title":"58th American Society of Hematology (ASH) Annual Meeting","article-title":"Efficacy of CD101, a novel echinocandin in prevention of Pneumocystis pneumonia (PCP): thwarting the biphasic life cycle of Pneumocystis","author":"Cushion","year":"2016"},{"key":"10.1016\/j.jgar.2018.02.013_bib0165","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01627-16","article-title":"Safety and pharmacokinetics of CD101 IV, a novel echinocandin, in healthy adults","volume":"61","author":"Sandison","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2018.02.013_bib0170","series-title":"ID\u00ae Week","article-title":"Pharmacokinetic\u2013pharmacodynamic target attainment analyses to support the selection of extended-interval CD101 dosing regimens","author":"Lakota","year":"2016"},{"key":"10.1016\/j.jgar.2018.02.013_bib0175","unstructured":"CD101 compared to caspofungin followed by oral step down treatment in subjects with candidemia and\/or invasive candidiasis-bridging extension (STRIVE). http:\/\/clinicaltrials.gov. [Accessed 24 January 2017]."}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716518300419?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716518300419?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:54:04Z","timestamp":1761990844000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716518300419"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":35,"alternative-id":["S2213716518300419"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2018.02.013","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rezafungin (CD101), a next-generation echinocandin: A systematic literature review and assessment of possible place in therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2018.02.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Ltd on behalf of International Society for Chemotherapy of Infection and Cancer.","name":"copyright","label":"Copyright"}]}}